{"id":51902,"date":"2024-07-18T18:58:47","date_gmt":"2024-07-18T16:58:47","guid":{"rendered":"https:\/\/www.fyb.de\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/"},"modified":"2024-07-18T18:58:47","modified_gmt":"2024-07-18T16:58:47","slug":"vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix","status":"publish","type":"post","link":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/","title":{"rendered":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>T\u00fcbingen\/ Berlin \u2014 YPOG provi\u00added compre\u00adhen\u00adsive legal advice to the lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal IV in the \u20ac 15 million Series C finan\u00adcing round of Hepa\u00adRe\u00adge\u00adniX GmbH. Exis\u00adting inves\u00adtors such as Novo Holdings, Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund and High-Tech Gr\u00fcn\u00adder\u00adfonds also parti\u00adci\u00adpa\u00adted in the investment.<\/p>\n<p>Hepa\u00adRe\u00adge\u00adniX GmbH is a company in the field of clini\u00adcal deve\u00adlo\u00adp\u00adment of novel thera\u00adpies for the treat\u00adment of acute and chro\u00adnic liver dise\u00ada\u00adses. Since its launch in 2017, Hepa\u00adRe\u00adge\u00adniX has successfully disco\u00advered and deve\u00adlo\u00adped seve\u00adral drug candi\u00adda\u00adtes for the treat\u00adment of acute and chro\u00adnic liver dise\u00ada\u00adses based on a novel mole\u00adcu\u00adlar target Mitogen-Acti\u00adva\u00adted Protein (MAP) Kinase Kinase 4 (MKK4). HRX-215 is a small mole\u00adcule inhi\u00adbi\u00adtor of mitogen-acti\u00adva\u00adted protein (MAP) kinase kinase 4 (MKK4). This subs\u00adtance has the poten\u00adtial to signi\u00adfi\u00adcantly support liver rege\u00adne\u00adra\u00adtion in pati\u00adents with liver meta\u00adsta\u00adses or primary liver tumors.<\/p>\n<p>The new funding will support the Phase Ib\/IIa clini\u00adcal trial, which will focus on impro\u00adving liver heal\u00ading and preven\u00adting liver failure.<\/p>\n<p><strong>Advi\u00adsor to Hepa\u00adRe\u00adge\u00adniX:&nbsp;YPOG<\/strong><\/p>\n<p>Dr. Martin Scha\u00adper (Lead, Tran\u00adsac\u00adtions), Part\u00adner, Berlin, Dr. Lutz Schrei\u00adber (IP\/IT\/Data Protec\u00adtion), Part\u00adner, Hamburg, Benja\u00admin M\u00fcller (Tran\u00adsac\u00adtions), Asso\u00adciate, Berlin, Matthias Treude (IP\/IT\/Data Protec\u00adtion), Asso\u00adciate, Hamburg, Cyra Ditt\u00adber\u00adner (Tran\u00adsac\u00adtions), Asso\u00adciate, Berlin<\/p>\n<p><strong>About Vesa\u00adlius Bioca\u00adpi\u00adtal&nbsp;IV<\/strong><\/p>\n<p>Vesa\u00adlius Bioca\u00adpi\u00adtal is an estab\u00adlished Euro\u00adpean life scien\u00adces venture capi\u00adtal inves\u00adtor with a long track record of consis\u00adtent returns, inves\u00adt\u00ading in the best\/\u00adfirst-class Euro\u00adpean biopharma and health\u00adtech companies.<\/p>\n<p>The company invests in attrac\u00adtive compa\u00adnies at an advan\u00adced stage of deve\u00adlo\u00adp\u00adment in the fields of drug deve\u00adlo\u00adp\u00adment, medi\u00adcal tech\u00adno\u00adlogy and diagno\u00adstics as well as eHealth\/mHealth, prima\u00adrily in Europe. The port\u00adfo\u00adlio compa\u00adnies address unmet medi\u00adcal and market needs and operate on the basis of strong intellec\u00adtual property protection.<\/p>\n<p><strong>About YPOG<\/strong><\/p>\n<p>YPOG is a law firm specia\u00adli\u00adzing in tax and commer\u00adcial law, active in the core areas of funds, tax, banking + finance and tran\u00adsac\u00adtions. The YPOG team advi\u00adses a wide variety of clients. These include emer\u00adging tech\u00adno\u00adlogy compa\u00adnies and family-run medium-sized enter\u00adpri\u00adses as well as corpo\u00adra\u00adti\u00adons and private equity\/venture capi\u00adtal funds. YPOG is one of the leading addres\u00adses for venture capi\u00adtal, private equity and fund struc\u00adtu\u00adring in Germany. The firm and its part\u00adners are ranked natio\u00adnally and inter\u00adna\u00adtio\u00adnally by JUVE, Best Lawy\u00aders, Legal 500, Focus, Cham\u00adbers and Part\u00adners and Leaders League. Today, YPOG employs more than 120 expe\u00adri\u00aden\u00adced lawy\u00aders, tax consul\u00adtants, tax specia\u00adlists and a notary in three offices in Berlin, Hamburg and Colo\u00adgne. http:\/\/www.ypog.law<\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>T\u00fcbingen\/ Berlin \u2014 YPOG provi\u00added compre\u00adhen\u00adsive legal advice to the lead inves\u00adtor Vesa\u00adlius Bioca\u00adpi\u00adtal IV in the \u20ac 15 million Series C finan\u00adcing round of Hepa\u00adRe\u00adge\u00adniX GmbH. Exis\u00adting inves\u00adtors such as Novo Holdings, Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund and High-Tech Gr\u00fcn\u00adder\u00adfonds also parti\u00adci\u00adpa\u00adted in the invest\u00adment. Hepa\u00adRe\u00adge\u00adniX GmbH is a company in the field of clinical&nbsp;[\u2026]<\/p>\n","protected":false},"author":2,"featured_media":51904,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1368,1369,1372,1373],"tags":[],"class_list":["post-51902","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-lawyers-tax-consultants-auditors","category-investors","category-consultant","category-venture-capital-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook<\/title>\n<meta name=\"description\" content=\"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook\" \/>\n<meta property=\"og:description\" content=\"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\" \/>\n<meta property=\"og:site_name\" content=\"FYB Financial Yearbook\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-18T16:58:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/v-4137102477.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"256\" \/>\n\t<meta property=\"og:image:height\" content=\"256\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Tatjana Anderer\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Tatjana Anderer\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\"},\"author\":{\"name\":\"Tatjana Anderer\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\"},\"headline\":\"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX\",\"datePublished\":\"2024-07-18T16:58:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png\",\"articleSection\":[\"General\",\"Featured\",\"News\",\"Lawyers, tax consultants, auditors\",\"Investors\",\"Consultant\",\"Venture Capital\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\",\"url\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\",\"name\":\"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook\",\"isPartOf\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png\",\"datePublished\":\"2024-07-18T16:58:47+00:00\",\"description\":\"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png\",\"width\":700,\"height\":286},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.fyb.de\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.fyb.de\/en\/#website\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"name\":\"FYB Financial Yearbook\",\"description\":\"For Your Business\",\"publisher\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.fyb.de\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.fyb.de\/en\/#organization\",\"name\":\"FYB Financial Yearbook\",\"url\":\"https:\/\/www.fyb.de\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"contentUrl\":\"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg\",\"caption\":\"FYB Financial Yearbook\"},\"image\":{\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce\",\"name\":\"Tatjana Anderer\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g\",\"caption\":\"Tatjana Anderer\"},\"description\":\"Gr\u00fcnderin des FYB-Verlag\",\"sameAs\":[\"http:\/\/neu.fyb.de\"],\"url\":\"https:\/\/www.fyb.de\/en\/author\/tanderer\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook","description":"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/","og_locale":"en_US","og_type":"article","og_title":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook","og_description":"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.","og_url":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/","og_site_name":"FYB Financial Yearbook","article_published_time":"2024-07-18T16:58:47+00:00","og_image":[{"width":256,"height":256,"url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/v-4137102477.jpg","type":"image\/jpeg"}],"author":"Tatjana Anderer","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Tatjana Anderer","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#article","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/"},"author":{"name":"Tatjana Anderer","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce"},"headline":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX","datePublished":"2024-07-18T16:58:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/"},"wordCount":404,"publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"image":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png","articleSection":["General","Featured","News","Lawyers, tax consultants, auditors","Investors","Consultant","Venture Capital"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/","url":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/","name":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX - FYB Financial Yearbook","isPartOf":{"@id":"https:\/\/www.fyb.de\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage"},"image":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png","datePublished":"2024-07-18T16:58:47+00:00","description":"YPOG provided comprehensive legal advice to the lead investor Vesalius Biocapital IV in the \u20ac 15 million Series C financing round of HepaRegeniX GmbH. Existing investors such as Novo Holdings, Boehringer Ingelheim Venture Fund and High-Tech Gr\u00fcnderfonds also participated in the investment.","breadcrumb":{"@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#primaryimage","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2024\/07\/vesalius-logo-1146051623-1.png","width":700,"height":286},{"@type":"BreadcrumbList","@id":"https:\/\/www.fyb.de\/en\/vesalius-biocapital-leads-e15-million-series-c-round-of-heparegenix\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fyb.de\/en\/"},{"@type":"ListItem","position":2,"name":"Vesalius Biocapital leads \u20ac15 million Series C round of HepaRegeniX"}]},{"@type":"WebSite","@id":"https:\/\/www.fyb.de\/en\/#website","url":"https:\/\/www.fyb.de\/en\/","name":"FYB Financial Yearbook","description":"For Your Business","publisher":{"@id":"https:\/\/www.fyb.de\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fyb.de\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.fyb.de\/en\/#organization","name":"FYB Financial Yearbook","url":"https:\/\/www.fyb.de\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","contentUrl":"https:\/\/www.fyb.de\/wp-content\/uploads\/2020\/06\/logo.svg","caption":"FYB Financial Yearbook"},"image":{"@id":"https:\/\/www.fyb.de\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/4308b3086925bc8567ceba3ebd69b4ce","name":"Tatjana Anderer","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fyb.de\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/11708a5289b743e6290bae8e4109e97efec1cb1ae5c7065f0bfc5c36f28c7757?s=96&d=mm&r=g","caption":"Tatjana Anderer"},"description":"Gr\u00fcnderin des FYB-Verlag","sameAs":["http:\/\/neu.fyb.de"],"url":"https:\/\/www.fyb.de\/en\/author\/tanderer\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/comments?post=51902"}],"version-history":[{"count":0,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/posts\/51902\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media\/51904"}],"wp:attachment":[{"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/media?parent=51902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/categories?post=51902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fyb.de\/en\/wp-json\/wp\/v2\/tags?post=51902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}